In further preclinical studies, a structurally similar galectin-3 inhibitor, GB1107, inhibited lung adenocarcinoma growth and metastasis, and augmented the tumor response to programmed death-ligand 1 blockade [7]. This evidence concerns the gene LGALS3 and lung adenocarcinoma.